{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:53:33Z","timestamp":1785920013672,"version":"3.56.0"},"reference-count":24,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:00:00Z","timestamp":1586563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Mantle cell lymphoma is a rare subtype of B-cell non-Hodgkin\u2019s lymphomas that is generally classified as an aggressive lymphoma requiring front-line chemo-immunotherapy with stem cell rescue. Despite effective treatment, many patients relapse or are refractory to front-line therapy. In addition, these patients may also develop drug resistance requiring novel modalities for subsequent lines. Bruton\u2019s tyrosine kinase inhibitors have demonstrated a well-tolerated safety and efficacy profile across several B-cell malignancies. Ibrutinib, acalabrutinib, and zanubrutinib are FDA-approved as treatment options for patients with Mantle cell lymphoma following one prior line of therapy. Various factors should be considered which include the adverse event profile of these agents and ability to adhere to therapy. In this article, we review the role of Bruton\u2019s tyrosine kinase inhibitors for the management of Mantle cell lymphoma and review the clinical pharmacology, pharmacokinetics, safety and efficacy, and future directions.<\/jats:p>","DOI":"10.1177\/1078155220915956","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T04:56:49Z","timestamp":1586581009000},"page":"1190-1199","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["The role of Bruton\u2019s tyrosine kinase inhibitors in the management of mantle cell lymphoma"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3467-9336","authenticated-orcid":false,"given":"Kirollos S","family":"Hanna","sequence":"first","affiliation":[{"name":"Pharmacy, Mayo Clinic College of Medicine, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Campbell","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Minnesota, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Husak","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Minnesota, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sturm","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Minnesota, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,4,11]]},"reference":[{"key":"bibr1-1078155220915956","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"bibr2-1078155220915956","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Version 7.2019. B-cell Lymphomas, www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (accessed 20 January 2020)."},{"key":"bibr3-1078155220915956","first-page":"1862","volume":"147","author":"Chadburn A","year":"1995","journal-title":"Am J Pathol"},{"key":"bibr4-1078155220915956","volume":"1000","author":"Schieber M","year":"2018","journal-title":"F1000Res"},{"key":"bibr5-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0836"},{"key":"bibr6-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0126-0"},{"key":"bibr7-1078155220915956","unstructured":"Imbruvica (ibrutinib) [prescribing information]. Sunnyvale, CA: Pharmacyclics, July 2019."},{"key":"bibr8-1078155220915956","unstructured":"Calquence (acalabrutinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, November 2019."},{"key":"bibr9-1078155220915956","unstructured":"Brukinsa (zanubrutinib) [prescribing information]. San Mateo, CA: BeiGene USA Inc., November 2019."},{"key":"bibr10-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"bibr11-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"bibr12-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0023-2"},{"key":"bibr13-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15411"},{"key":"bibr14-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"bibr15-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0575-9"},{"key":"bibr16-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1002\/hon.15_2629"},{"key":"bibr17-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1002\/hon.55_2630"},{"key":"bibr18-1078155220915956","unstructured":"FDA. Hematology\/oncology (cancer) approvals & safety notification, www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm279174.htm (accessed 4 January 2020)."},{"key":"bibr19-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"bibr20-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1003-6"},{"key":"bibr21-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-019-01124-1"},{"key":"bibr22-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-737346"},{"key":"bibr23-1078155220915956","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5091"},{"key":"bibr24-1078155220915956","first-page":"223","volume":"17","author":"Bond DA","year":"2019","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220915956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220915956","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220915956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:52Z","timestamp":1777688572000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220915956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1177\/1078155220915956"],"URL":"https:\/\/doi.org\/10.1177\/1078155220915956","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,11]]}}}